Sincalide
Also known as: C-CCK-8, Caerulein analog, CCK-8, CCK-8S, Cholecystokinin octapeptide, Kinevac
Source Sincalide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sincalide is a synthetic analogue of the C‑terminal octapeptide of cholecystokinin (CCK‑8) that is administered intravenously to provoke gallbladder contraction. It is primarily employed as a pharmacologic cholecystagogue during hepatobiliary scintigraphy (cholescintigraphy) to assess gallbladder ejection fraction and to aid the diagnosis of conditions such as chronic acalculous gallbladder disease, acute cholecystitis, and biliary obstruction.
Mechanism of Action
Sincalide mimics the natural peptide hormone cholecystokinin and binds to CCK‑A (CCK1) receptors on gallbladder smooth‑muscle cells. Receptor activation triggers intracellular calcium release, leading to coordinated smooth‑muscle contraction, accelerated bile flow, and emptying of the gallbladder. The resulting physiologic response is used as a diagnostic stimulus in imaging studies.
What the Research Shows
Clinical literature focuses on sincalide’s role in diagnostic imaging. A 2019 review outlines the standard infusion of 0.02 µg/kg over 60 minutes and notes its widespread use in cholescintigraphy for chronic acalculous gallbladder disease. A 2004 review of five human studies in parenteral‑nutrition patients reported that 0.04 µg/kg IV three times daily increased bile flow and improved bilirubin, though efficacy was absent in advanced liver disease and long‑term outcomes remain unknown. Reviews from 1991 and 2014 highlight sincalide pretreatment as a routine maneuver to improve gallbladder visualization and reduce examination time. A 2015 systematic review reported that shortages of sincalide have prompted the use of fatty meals as alternative cholecystagogues, though normal reference values vary.
Reported Benefits
When used as intended, sincalide reliably stimulates gallbladder contraction, enhancing visualization of the organ and allowing accurate measurement of ejection fraction during scintigraphy. In patients receiving parenteral nutrition, short‑term sincalide therapy has been shown to increase bile flow and modestly improve laboratory markers of cholestasis. Its pharmacologic effect also shortens imaging time when combined with morphine augmentation in acute cholecystitis assessments.
Limitations of the Evidence
Evidence is limited to imaging contexts and small, non‑randomised human studies for therapeutic use. Availability can be inconsistent, requiring compounded pharmacy preparations or substitution with fatty meals, which lack standardized normal values. The drug appears ineffective in patients with advanced liver disease, and there are no data on long‑term outcomes or disease‑modifying benefits. No large‑scale trials have compared sincalide directly with alternative cholecystagogues.
Safety Considerations
The abstracts do not report specific adverse events, but as a CCK analogue, sincalide may cause abdominal cramping, nausea, or transient hypotension. Certain medications that inhibit gallbladder contraction should be withheld for at least 48 hours before imaging. Caution is advised in patients with severe liver dysfunction, where therapeutic response is limited. Standard clinical monitoring during infusion is recommended.
How It Is Administered
Sincalide is administered intravenously. For cholescintigraphy, the commonly cited regimen is 0.02 µg/kg infused over 60 minutes. In studies of parenteral‑nutrition‑associated disease, a dose of 0.04 µg/kg given three times daily IV was used. When commercial product is unavailable, pharmacy‑compounded sincalide may be employed; oral fatty meals are an alternative for gallbladder stimulation.
Routes of Administration
Goals & Uses
- Pancreatic secretion stimulationResearchModerate
- Assessment of gallbladder ejection fractionDiagnosticHigh
- Acceleration of small bowel barium transitDiagnostic ImagingModerate
- Stimulation of pancreatic enzyme secretionDiagnosticHigh
- Gallbladder contraction for cholecystographyDiagnostic ImagingHigh
- Research tool for CCK receptor studiesResearchHigh
- Gallbladder ejection fraction testingDiagnosticHigh
Contraindications
- Intestinal obstructionGastrointestinalModerate
- Hypersensitivity to sincalide or CCK analogsAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to sincalideAllergyHigh
- Severe acute pancreatitisGastrointestinalModerate
Adverse Effects
- Abdominal discomfort/crampingGastrointestinalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- Abdominal crampingGastrointestinalCommon
Drug Interactions
- Anticholinergic agentsLow
- Opioid analgesicsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with suspected acute pancreatitisGastrointestinalRelative
Regulatory Status
- European UnionInvestigationalNot widely marketed; used in clinical studies
- United StatesApprovedApproved: Gallbladder ejection fraction testing, Pancreatic function testingDiagnostic use only
- United KingdomUnknownLimited marketing authorization data available for the UK.
Approved by the FDA for diagnostic use. Administered intravenously under medical supervision. Not for therapeutic use.
Evidence & Sources
- Journal ArticleModerateZiessman HA2019-01-01T00:00:00.000000Z
- Journal ArticleModeratePrescott WA Jr, Btaiche IF2004-01-01T00:00:00.000000Z
- Journal ArticleHighFotos JS, Tulchinsky M2015-01-01T00:00:00.000000Z
- Journal ArticleModerateZiessman HA2014-01-01T00:00:00.000000Z
- Journal ArticleModerateGrossman SJ, Joyce JM1991-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the primary clinical use of sincalide?
Sincalide is primarily used as a pharmacologic cholecystagogue during hepatobiliary scintigraphy to stimulate gallbladder contraction, allowing measurement of ejection fraction and improving diagnostic accuracy for gallbladder disease.
How is sincalide dosed for imaging studies?
The standard imaging protocol recommends an intravenous infusion of 0.02 µg per kilogram of body weight administered over a 60‑minute period. This regimen has been validated in multiple clinical reviews.
Can sincalide treat gallbladder disease in patients on parenteral nutrition?
Short‑term studies suggest sincalide can increase bile flow and improve bilirubin levels in such patients, but its effectiveness in advanced liver disease is unclear and long‑term therapeutic benefit has not been established.
What alternatives exist if sincalide is unavailable?
When sincalide cannot be sourced, clinicians may use fatty‑meal cholecystagogues such as certain infant formulas or Ensure Plus, although normal gallbladder ejection values for these alternatives are less well defined.
Are there any safety concerns with sincalide?
While specific adverse events are not detailed in the cited literature, sincalide, as a CCK analogue, can cause abdominal discomfort, nausea, or transient blood pressure changes. It should be avoided in patients with severe liver disease and used after withholding drugs that inhibit gallbladder contraction for 48 hours.
What is Sincalide used for?
Sincalide is educationally associated with: Pancreatic secretion stimulation, Assessment of gallbladder ejection fraction, Acceleration of small bowel barium transit, Stimulation of pancreatic enzyme secretion, Gallbladder contraction for cholecystography, Research tool for CCK receptor studies, Gallbladder ejection fraction testing. Educational only — not medical advice.
How is Sincalide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Sincalide?
Reported adverse effects include: Abdominal discomfort/cramping, Hypotension, Flushing, Nausea, Vomiting, Dizziness, Abdominal cramping. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sincalide?
Recorded contraindications: Intestinal obstruction, Hypersensitivity to sincalide or CCK analogs, Pregnancy, Known hypersensitivity to sincalide, Severe acute pancreatitis. Consult a qualified clinician before use.